Fundamentals in Focus for Novartis AG (NVS)

Novartis AG (NYSE:NVS) is an interesting stock at present. Now trading with a market value of 216.39B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Novartis AG (NYSE:NVS) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NVS, the company currently has 7.58 billion of cash on the books, which is offset by 8.33 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 132.11 billion in total assets, balanced by 64.4 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Novartis AG (NVS) saw 1.71 billion in free cash flow last quarter, representing a quarterly net change in cash of 566.95 million. Perhaps most importantly where cash movements are concerned, the company saw about 2.05 billion in net operating cash flow.

Is Novartis AG (NYSE:NVS) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 11.58 billion in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the NVS saw sales decline by -0.06.

But what about the bottom line? After all, that’s what really matters in the end. Novartis AG (NVS) is intriguing when broken down to its core data. The cost of selling goods last quarter was 4.12 billion, yielding a gross basic income of 7.46 billion. For shareholders, given the total diluted outstanding shares of 2.39 billion, this means overall earnings per share of 0.70. Note, this compares with a consensus analyst forecast of 1.16 in earnings per share for its next fiscal quarterly report.

Novartis AG (NYSE:NVS) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 5.01 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 16.08. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Novartis AG.

Previous ArticleNext Article

Related Post

Should You Invest in Abbott Laboratories (ABT)? A ... Recent insider trends for Abbott Laboratories (NYSE:ABT) have caught the attention of investors. Insider activity is often a strong indicator of futur...
Should You Invest in National CineMedia (NCMI)? A ... Recent insider trends for National CineMedia, Inc. (NASDAQ:NCMI) have caught the attention of investors. Analysts monitor insider data to understand t...
Are ARCA biopharma, Inc. (ABIO)’s Recent Own... Recent insider trends for ARCA biopharma, Inc. (NASDAQ:ABIO) have caught the attention of investors. Insider data is useful because it can reveal what...
Dissecting the Insider Trading Patterns of Marinus... Recent insider trends for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have caught the attention of investors. Insider data is useful because it can re...
Why CytomX Therapeutics, Inc. (CTMX) Is Being Adde... CytomX Therapeutics, Inc. (NASDAQ:CTMX) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participant...

Leave a Reply

Your email address will not be published.